1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

If you watched this year's iPhone launch event, you could've been forgiven for thinking that the iPhone XS is the most underwhelming 'S' upgrade in the iPhone's history. Apple spent surprisingly ...

If you watched this year's iPhone launch event, you could've been forgiven for thinking that the iPhone XS is the most underwhelming 'S' upgrade in the iPhone's history. Apple spent surprisingly ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...